Gluten ataxia is an autoimmune condition where the body’s reaction to gluten damages the cerebellum, the part of the brain that controls balance and coordination. It accounts for about 15% of all ataxias and a striking 40% of cases where no other cause can be found. Unlike celiac disease, which attacks the gut lining, gluten ataxia can occur without any digestive symptoms at all, making it easy to miss.
How Gluten Damages the Cerebellum
When someone with gluten ataxia eats gluten, their immune system produces antibodies against gliadin, a protein in wheat. Those antibodies don’t just target gliadin in the gut. They cross-react with Purkinje cells, the large neurons in the cerebellum responsible for coordinating movement. Research from the Sheffield Ataxia Centre found that sera from nearly all gluten ataxia patients (12 of 13) stained Purkinje cells strongly, confirming this cross-reactivity.
What makes gluten ataxia distinct from celiac disease is which tissue the immune system primarily attacks. In celiac disease, antibodies target an enzyme called transglutaminase 2 (TG2) in the gut lining. In gluten ataxia, a different version of that enzyme, transglutaminase 6 (TG6), found in brain tissue, appears to be the main target. This is why the condition can damage the brain while leaving the intestines relatively untouched. Only about 24% of people with gluten ataxia show the intestinal damage typical of celiac disease.
Over time, the immune attack causes inflammation, loss of Purkinje cells, and activation of immune cells called microglia throughout the cerebellar tissue. Post-mortem studies of confirmed cases show severe atrophy of the cerebellar cortex, with near-total loss of Purkinje cells in advanced disease. This damage is what makes early diagnosis so important: once those neurons are gone, they don’t grow back.
What Gluten Ataxia Feels Like
The hallmark symptom is progressive difficulty with balance and walking. Most people develop a wide-based, unsteady gait that worsens over months or years. The onset is typically gradual rather than sudden, with an average age of presentation around 53.
Beyond gait problems, gluten ataxia usually involves broader cerebellar dysfunction:
- Limb coordination problems: difficulty with precise hand movements, such as bringing a finger to your nose smoothly
- Slurred or scanning speech: a halting, irregular rhythm to words caused by poor coordination of the muscles involved in speaking
- Difficulty with rapid alternating movements: trouble flipping your hands back and forth quickly, a sign called dysdiadochokinesia
In rare cases, the condition can also involve involuntary jerking movements (myoclonus), tremor of the palate, or rapid chaotic eye movements. The condition is described as “purely cerebellar,” meaning it primarily affects coordination rather than causing numbness, weakness, or cognitive decline, though some patients also develop gluten-related nerve damage in the hands and feet.
How It’s Diagnosed
Diagnosing gluten ataxia can be tricky because there’s no single definitive test. The process typically starts when a doctor can’t find another explanation for progressive ataxia, such as a genetic cause, a stroke, or alcohol-related damage. At that point, blood tests for gluten sensitivity become part of the standard workup.
The most commonly available tests look for antibodies against gliadin and TG2 (the same antibody used to screen for celiac disease). Testing for TG6 antibodies is more specific to neurological involvement. About 62% of gluten ataxia patients carry TG6 antibodies, compared to 45% of people with celiac disease who have no neurological symptoms. TG6 antibodies can also identify gluten sensitivity in ataxia patients who lack digestive symptoms or other markers that would point toward gluten as the culprit, though their role in diagnosis is still debated.
Brain imaging plays a supporting role. MRI scans may reveal cerebellar atrophy in patients with longstanding disease, and a specialized technique called MR spectroscopy can detect reduced levels of a brain chemical that signals neuron health, even before visible shrinkage appears. However, MRI can also look completely normal in earlier stages, so a clean scan doesn’t rule out the diagnosis.
One important point: a negative intestinal biopsy does not rule out gluten ataxia. Since roughly three-quarters of patients have no gut damage, requiring a celiac diagnosis before considering neurological gluten sensitivity would miss most cases. Researchers have emphasized that patients with positive blood markers and negative biopsies should still be treated.
Treatment With a Gluten-Free Diet
A strict gluten-free diet is the first-line treatment. The goal is to eliminate the immune trigger entirely, allowing the inflammation in the cerebellum to subside. “Strict” matters here. Even small, repeated exposures to gluten can keep the immune response active.
How much improvement you can expect depends largely on how early treatment starts. Patients whose cerebellums have not yet developed significant atrophy tend to respond best. When Purkinje cells are still intact but inflamed, removing gluten can lead to meaningful recovery of coordination and balance. Once those cells have died and the cerebellum has visibly shrunk on imaging, the damage is largely irreversible, though stopping further progression is still valuable.
Clinical improvement with dietary adherence has been documented across multiple studies, and the presence or absence of intestinal damage does not predict whether the cerebellum will respond to a gluten-free diet. In other words, even patients without celiac disease on biopsy can see neurological benefit. Doctors typically monitor gluten-related antibody levels over time to confirm the diet is working and that the immune response is fading.
When Diet Alone Isn’t Enough
Some patients don’t improve on a gluten-free diet, or their condition continues to progress despite strict adherence. In these cases, treatments that directly suppress the immune system become the next step. Intravenous immunoglobulin (IVIg) infusions have shown satisfactory results in patients who failed dietary therapy, with both clinical and blood marker improvements.
A particularly difficult subtype involves myoclonic ataxia associated with refractory celiac disease, where both the neurological symptoms and the intestinal malabsorption persist despite a strict diet. For these patients, immune-suppressing medications have been reported to improve both the cerebellar symptoms and nutrient absorption. The general approach is to try the gluten-free diet first, confirm antibody levels have dropped, and escalate to immune therapy only if symptoms persist after the immune markers have normalized.